R1 Therapeutics is developing innovative, category-defining therapeutics for patients with kidney disease.
Location: United States
Total raised: $77.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.03.2026 | Series A | $77.5M | F-Prime Ca... |
Mentions in press and media 5
| Date | Title | Description |
| 17.03.2026 | R1 Therapeutics: $77.5 Million Raised To Advance Kidney Disease Treatment | R1 Therapeutics, a clinical-stage biopharmaceutical company focused on kidney disease, has launched with an oversubscribed $77.5 million Series A financing to advance a first-in-class treatment for hyperphosphatemia in patients with chronic... |
| 17.03.2026 | R1 Therapeutics launches with $77.5M Series A to advance first-in-class kidney disease treatment AP306 | For decades, hyperphosphatemia in chronic kidney disease has been treated with therapies that often fall short. Now, a new biotech startup, R1 Therapeutics, is aiming to change that with fresh funding and a different approach. The company h... |
| 17.03.2026 | R1 Therapeutics Raises $77.5M in Series A Funding | R1 Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $77.5M in Series A funding. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, with participation from Curie.Bio, SymBiosis, and ... |
| 17.03.2026 | Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306 | AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, an... |
| - | R1 Therapeutics | “R1 Therapeutics is developing innovative, category-defining therapeutics for patients with kidney disease.” |